Knee osteoarthritis Musculoskeletal Diseases Polyarthrosis
Conditions
Interventions
The patients, after a complete verbal/questionnaire evaluation, clinical evaluation, anthropometric measurement evaluation (as prescribed by the Davis protocol), and an evaluation with the NRS and WOM
the total duration of treatment was 14 days.
The control group was an intra-patient control group: the study product was administered in the OA knee while the controlateral knee was considered as in
Sponsors
Fidia Farmaceutici S.p.A. (Italy)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged at least 40 years old, either sex 2. Presence of grade 2 or 3 (according to the Kellegren and Lawrence scale) osteoarthritis (OA) of one knee 3. Knee with pain greater than 4 on the Numerical Rating Scale (NRS)
Exclusion criteria
Exclusion criteria: 1. Concurrent presence of pathologies such as rheumatoid arthritis, gout, hip arthritis 2. Presence of skin infections near the knee 3. Use of corticosteroid in the last 3 months 4. Simultaneous anticoagulant therapy 5. Use of joint protective drugs 6. Clotting anomalies 7. Knee valgus 8. Known adverse reactions to hyaluronic acid 9. Presence of knee replacement or impending knee replacement surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improving walking parameters: GAIT Analysis, measured at baseline (T1), and after 45 days (T2). | — |
Secondary
| Measure | Time frame |
|---|---|
| Reducing pain: 1. Western Ontario and McMaster Universities osteoarthritis (OA) index (WOMAC) scale 2. Numerical rating scale Measured at baseline (T1), and after 45 days (T2). | — |
Countries
Italy
Outcome results
None listed